Topics

Alkermes Announces New Data From ALKS 4230 Clinical Development Program at Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting

07:01 EST 8 Nov 2019 | FinanzNachrichten

? Preliminary Safety and Efficacy Data From ARTISTRY-1 Show Signs of Clinical Benefit and Tolerability of ALKS 4230 as Monotherapy and in Combination With Pembrolizumab - ? Posters and a Corporate...

Original Article: Alkermes Announces New Data From ALKS 4230 Clinical Development Program at Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting

NEXT ARTICLE

More From BioPortfolio on "Alkermes Announces New Data From ALKS 4230 Clinical Development Program at Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting"

Quick Search